Sancerre (FR)
{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~79 mi. (Orléans, France, +226 more cities)
facility
Centre Hospitalier Regional du Orleans ( Site 0430)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~79 mi. (Orléans, France, +93 more cities)
facility
Centre Hospitalier Regional du Orleans ( Site 0463)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
city
~96 mi. (La Chaussée-Saint-Victor, France, +84 more cities)
facility
Site FR33016
biomarker
CLDN18 Expression
condition
Pancreatic Adenocarcinoma
drug
gemcitabine, +2 more drugs
drug type
chemotherapy, +1 more type